AI-Designed Drugs by a DeepMind Spinoff Are Headed to Human Trials
WIRED
Isomorphic Labs, a DeepMind spinoff, is preparing to initiate human clinical trials for drugs developed using its Nobel Prize-winning AI technology.Summary
Isomorphic Labs, a biotech company spun off from Google DeepMind, is transitioning its AI-designed drug candidates into human clinical trials. Leveraging the revolutionary protein-folding capabilities of AlphaFold and its proprietary drug-design engine, IsoDDE, the company aims to create highly potent, lower-dose medications with fewer side effects. Despite earlier timelines, the company is actively collaborating with industry giants like Eli Lilly and Novartis while pursuing an ambitious long-term mission to revolutionize the treatment of diseases in fields such as oncology and immunology.
(Source：WIRED)